Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Provexis Plc | LSE:PXS | London | Ordinary Share | GB00B0923P27 | ORD 0.1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.5235 | 5,476 | 08:03:30 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 0.452 | 0.595 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Food Preparations, Nec | 802k | -586k | -0.0003 | -17.33 | 11.61M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 09:52:33 | O | 5,476 | 0.4592 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 25/10/2024 | 14:47 | UK RNS | Provexis PLC Result of AGM |
| 30/9/2024 | 12:43 | ALNC |  EARNINGS: Katoro Gold pretax loss narrows; Ondine Biomedical sales up |
| 30/9/2024 | 06:00 | UK RNS | Provexis PLC Final Results |
| 30/4/2024 | 16:00 | UK RNS | Provexis PLC Total Voting Rights |
| 03/4/2024 | 09:59 | ALNC | TRADING UPDATES: Quiz sales fall, names new CEO; Byotrol eyes AIM exit |
| 28/3/2024 | 07:00 | UK RNS | Provexis PLC Issue of Equity - purchase of Fruitflow® II SD |
| 29/12/2023 | 13:57 | ALNC | IN BRIEF: Provexis first-half loss widens but positive for Fruitflow |
| 29/12/2023 | 12:48 | UKREG | Provexis PLC Half-year Report |
Provexis (PXS) Share Charts1 Year Provexis Chart |
|
1 Month Provexis Chart |
Intraday Provexis Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 17/11/2024 | 12:33 | Provexis: a new beginning | 2,841 |
| 30/9/2020 | 19:59 | PROVEXIS PLC (Sirco) | 40,155 |
| 27/4/2013 | 11:43 | Blatherskites, trolls, bashers & duplicitous 'investors' | 631 |
| 04/9/2012 | 16:24 | PXS herd mentality, medicine, moneymen and manipulation | 3,710 |
| 20/6/2012 | 00:07 | The Pixies 'Time To Grow Your Tomatoes' Thread | 54 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 09:52:34 | 0.46 | 5,476 | 25.15 | O |
| 2024-11-20 16:08:49 | 0.46 | 7,948 | 36.50 | O |
| Top Posts |
|---|
Posted at 21/11/2024 08:20 by Provexis Daily Update Provexis Plc is listed in the Food Preparations, Nec sector of the London Stock Exchange with ticker PXS. The last closing price for Provexis was 0.52p.Provexis currently has 2,217,821,523 shares in issue. The market capitalisation of Provexis is £11,532,672. Provexis has a price to earnings ratio (PE ratio) of -17.33. This morning PXS shares opened at - |
Posted at 28/10/2024 12:36 by huntergls RP, anyone looking in from the outside may see your view as more of grudge at IF rather than PXS as a company. This Australia thing is obviously got to you. I don't care where he lives just as long as he gets us to the end game. As he explained it's a lot of work negotiation with suppliers, getting the deal with Bi-Health, getting a better deal with DSM, and sorting PXS Ireland. He has got Luke back on board and does his level best to reduce placings. If you would have gone to the AGM you could have explained your worries. Anyone can do this via chat sites. All the ones at the AGM are all in it for the end game, not a quick pump and dump. We have all been in a long time yes but let's give it another 12-18 months. I am 99% confident things will work out really eell |
Posted at 27/10/2024 08:07 by gix er redprince, without very much knowledge of Asset Match I cannot comment on it either way. Good or bad.I would be gobsmacked if this was the first time that SL has suggested AM to IF so I am pretty sure IF knows the benefits/drawbacks of the platform but yet we are still on AIM with no formal news from the company. Talk of going private is just talk with nothing to suggest that this is the plan so as you say "I take that with a good measure of salt" IF has outlined what his long term hopes are for the company. "he hoped that both DSM and By-Health would eventually wish to purchase the equity of PXS and hoped that any bidding war would only serve to get the best deal for shareholders." In an ideal world I agree but the possibilities are there. |
Posted at 27/10/2024 07:14 by gix er winner, As it was SL that made the suggestion we could assume that he would like Provexis to move from AIM to Asset Match.I know very little about the platform so have no idea if it would be good or bad for PXS/shareholders. One downside to shareholders (IMO) would be the lack of being able to trade whenever they want. |
Posted at 26/10/2024 13:13 by informer Gents - there were in fact 6 members in attendance at yesterdays AGM including Mr Lucas ( those it was suggested with a combined holding of approx 20% share equity)Following the formal business Mr Chairman invited questions with as usual a reminder that no information could be provided which could be construed as price sensitive. In answer to most questions members were reminded to refer to the recent Report and Accounts where the majority of information could be found. IF re-confirmed that the relationship between us and DSM and By-Health was exceptionally strong and at top level and proceeded to give an impressive visual presentation in support of the significant direct sales growth showing in excess of 20 different products from different customers of PreMix predominantly from Europe, the middle and Far East. Ford was questioned as to his time commitment and his aims and ambitions for shareholders - the Chairman offered his support to the CEO confirming that he was putting in way in excess of the average daily shift - members had reported speaking to him often very late into the evening. Contrary to the views of the few IF dissenters on this chat Mr Lucas was outspoken in his belief that Ford had in fact a very poor incentive deal - the CEO responded that he was totally committed to the end game where he hoped that both DSM and By-Health would eventually wish to purchase the equity of PXS and hoped that any bidding war would only serve to get the best deal for shareholders. IF also confirmed the royalties agreement over the next four years reduces annually thus improving the "Margin" It was difficult to glean any further specific information in this respect as each is covered by individual Confidentiality Agreements. In respect of the SAMR approval there is an explanation within the Result of AGM RNS with a link to an article under Notes for Editors via nutraingredients-asi IF suggested reference be made once again to the Outlook statement within Report and Accounts and in respect of future funding for the inevitable re-manufacture of PreMix stock various options were being considered - whilst current figures would support approval by Commercial lenders the projected double digit interest rates were not very inviting. Asking for a 'whip round' from selected shareholders could be a more likely preference. Finally Stuart made a case that the AIM listing offered very little to the company its shareholders and specifically himself and that the annual cost of approx £50k is unwarranted. IF in response suggested this was a discussion be continued between ourselves - that being said the 6 members duly retired to the pub followed by a hearty lunch which as I recall went on until way after sunset. I have however no recollection of there being any further discussion in this respect - any views in support of SL would surely be communicated back to him. Don't shoot the messenger ........ |
Posted at 23/10/2024 06:17 by sigma3333 redprinceI recall PXS were given a dressing down over the concert party raid in 2009 - the former CEO indeed took the opportunity to make a significant profit from stock options. Although only my opinion, I believe the current CEO behaviour is to avoid another P&D. The one person that has kept PXS going is gixer - in fact the latest find around from Duttaroy is very exciting. The CEO has lived off the prospect of blue cap/China for nearly 10 years now. If it doesn’t happen by end of this year then I believe time for a SR. (by the way I firmly believe gixer is the curent CEO, or works for PXS). siggy |
Posted at 22/10/2024 19:57 by redprince Gixer yes this is what i am referring to.. A royalty is payable to DSM on the gross profits generated from Fruitflow sales to customers transferred from DSM over the first four years of the Transfer of Business agreement. From 1 January 2023 the net profit accruing to Provexis on sales of Fruitflow in the calendar year - on a pro-forma basis, assuming like for like sales and margins - would be materially ahead of the net share of the profit that would have accrued to Provexis with like for like sales and margins under the existing 2010 Alliance Agreement; on the same pro-forma basis, assuming like for like sales and margins, the net profit accruing to Provexis would further increase in each of the subsequent three calendar years. The year ended 31 March 2024 therefore included nine months of the royalty at the first year rate to 31 December 2023, and three months of the royalty at the lower second year rate. Royalties payable to DSM are included in cost of goods. The terms of the Transfer of Business agreement otherwise remain strictly confidential between the Company and DSM. Fruitflow II SD sales of more than £724k have been made in the 2024/25 financial year period from 1 April 2024 to 30 September 2024, more than 11% ahead of the full year sales for the year ended 31 March 2024. In addition to the sales made so far in the 2024/25 financial year, confirmed sales orders for Fruitflow II SD in excess of £190k are currently being processed. The Company is dealing with numerous sales enquiries from existing and new customers for further direct sales of Fruitflow in 2025 and beyond. On 28 March 2024 the Company announced that it had agreed to purchase a further batch of Fruitflow II SD inventory from DSM, to satisfy increasing demand for Fruitflow. The inventory purchase totalled £341,000, and on 5 April 2024 Provexis issued 45,123,732 new ordinary shares of 0.1p each in the Company to DSM in part satisfaction of the inventory purchase, with the remainder of the inventory purchase to be paid for in cash. A reconciliation of the underlying operating loss to statutory operating loss is provided below: 2024 2023 Rev 801,964 389,916 COS (518,169) (95,497) Gross profit 283,795 294,419 Our gross margin was materially worse which is at odds with the above statement. Once again IF has imo been deliberately vague and actually misleading in the way the accounting information is presented.If your net profit was expected to be better it is reasonable to assume all other things being equal that your margin was better. He appears to have accounted for the stock that was paid for but not that which was yet to be settled. You normally only count in cos the cost of stock in the sales being reported. So why did he count all the stock that had been paid? It makes a mockery of the original claim about improved net profit. Accounts are meant to inform the user but ours even after 15 years never leave us much if any wiser. The usual smoke and mirrors from pxs. |
Posted at 15/8/2024 16:16 by bareknee SmithiePart of what you say is true, but to get there your workings out are a bit ropey. The bit that I'd say you're right about relates to cashflow and PXS having to, or choosing to, issue shares to DSM Firmenich as part payment for a batch of FF. When the results come out in September we'll know, or have a very good idea, as to whether or not we had the cash to pay for that FF and continue operating or not. I suspect we didn't, so it was a way of keeping the wheels turning until we're either cashflow positive, can borrow against future sales or issue more shares in a placing. So there's a big risk there. Where your working out is dodgy relates to the B2B relationship between PXS and DSM. They don't make Fruitflow, they just have some in store which they pretty much can't sell to anyone except PXS, so it's an unusual situation and will likely unravel quite soon ( if it hasn't already ). At that point PXS will have to go to the manufacturer which supplied FF to DSM and negotiate a contract. The issues on cashflow will almost certainly be the same as they are between us and DSM now and, if they can't be resolved, then it's Goodnight Vienna time. Previously our Chief Exec has been able to keep things going via placings,so that's the obvious route to go. What we don't know is if, or more likely when the Chinese company ByHealth, who want to launch over there, will get permission from their regulator. If they get that permission in a timely manner and put decent sized orders in, then borrowing against that gets much easier, as does convincing people to take part in a placing. At that point the hope is that PXS is then profitable, has manageable cashflow and becomes a proper business. What the share price was years ago is immaterial. It was plainly massively overvalued, but that's in the past. |
Posted at 15/8/2024 14:43 by smithie6 ...one can look at it from different viewpointsone viewpoint is that the co. does not have enough cash to buy product from a stockist imo that is bad & it probably continues a never ending sequence of dilution & more dilution ... imo that is also bad. ---- & from my viewpoint the owner of the IP, PXS, should be receiving cash generated from sales which for PXS should imo be globally located re-sellers/agents so, imo, PXS should not be buying stock from a seller, the seller should be selling it shops & Joe Public....it infers that the agent was not able to sell it, imo. stock coming back to PXS is not a +ve sign imo |
Posted at 13/8/2024 19:23 by smithie6 ..what's the story here nowadays ?...the owns intel. prop. in some food product which apparently has some health benefits, yes ? but to obtain the product to then supply it to others the co. has to issue a lot of shares to some overseas third party, who apparently make the product, yes ? so, one assumes that PXS itself is virtually bankrupt since it can not pay cash to obtain its own product, to then sell it (at a higher price) All seems "very strange" to me. Surely, normal business practice would be that the mfr makes the stuff, supplies it to PXS (with an invoice asking to be paid) & PXS ships the stuff to clients for cash on delivery or cash in say 10 days. And then PXS pays the product mfr, within 60-90 days. And everyone is happy. And PXS keeps the nett gross profit on its sales. Step & repeat. but no, PXS issues 2% of the shares of PXS to the product mfr. !! seems insane to me. The only logical justification I can see is that PXS is verging on bankruptcy & no one is willing to supply the product without getting paid at delivery, & PXS can not pay, since it pays using shares. It all seems a bit strange imo. ====== Other companies that have relentlessly issued new shares include Craven House. Another disaster. ---- looking at the "all time" chart for PXS, it looks similar perhaps to a hospital monitor display for someone and the last activity on the monitor was in 2010 ! ...& that since then it has just flat lined ! While on the 2 year chart it looks like the sick patient briefly wakes up once per year...only to then slide further downhill ! |
Posted at 28/6/2024 18:17 by sigma3333 IF has boxed pxs into a corner controlled by the Chinese government. If blue cap isn’t granted what happens after the share price collapse ?ciggy |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
